Education
About Us
Working with TipRanks
Follow Us
Viva Biotech Holdings (HK:1873)
:1873
RESEARCH TOOLSreports
Total Valuation
Viva Biotech Holdings has a market cap or net worth of HK$3.19B. The enterprise value is HK$5.06B.
Market CapHK$3.19B
Enterprise ValueHK$5.06B
Share Statistics
Viva Biotech Holdings has 2,128,434,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,128,434,300
Owned by Insiders―
Owned by Institutions0.01%
Financial Efficiency
Viva Biotech Holdings’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 2.66%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)2.66%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee962.99K
Profits Per Employee143.34K
Employee Count2,063
Asset Turnover0.28
Inventory Turnover4.76
Valuation Ratios
The current PE Ratio of Viva Biotech Holdings is 10.32. Viva Biotech Holdings’s PEG ratio is 0.02.
PE Ratio10.32
PS Ratio0.00
PB Ratio0.81
Price to Fair Value0.45
Price to FCF21.33
Price to Operating Cash Flow7.55
PEG Ratio0.02
Income Statement
In the last 12 months, Viva Biotech Holdings had revenue of 1.99B and earned 167.29M in profits. Earnings per share was 0.08.
Revenue1.99B
Gross Profit687.40M
Operating Income229.67M
Pretax Income295.70M
Net Income167.29M
EBITDA428.00M
Earnings Per Share (EPS)0.08
Cash Flow
In the last 12 months, operating cash flow was 152.33M and capital expenditures -128.35M, giving a free cash flow of 23.98M billion.
Operating Cash Flow152.33M
Free Cash Flow23.98M
Free Cash Flow per Share0.01
Dividends & Yields
Viva Biotech Holdings pays an annual dividend of HK$0.01, resulting in a dividend yield of ―
Dividend Per ShareHK$0.01
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.22
52-Week Price Change190.57%
50-Day Moving Average1.63
200-Day Moving Average1.19
Relative Strength Index (RSI)42.00
Average Volume (3m)6.02M
Important Dates
Viva Biotech Holdings upcoming earnings date is Aug 28, 2025, Before Open (Confirmed).
Last Earnings DateMar 27, 2025
Next Earnings DateAug 28, 2025
Ex-Dividend DateJun 16, 2021
Financial Position
Viva Biotech Holdings as a current ratio of 1.67, with Debt / Equity ratio of 78.31%
Current Ratio1.67
Quick Ratio1.42
Debt to Market Cap0.73
Net Debt to EBITDA0.80
Interest Coverage Ratio4.26
Taxes
In the past 12 months, Viva Biotech Holdings has paid 73.72M in taxes.
Income Tax73.72M
Effective Tax Rate0.25
Enterprise Valuation
Viva Biotech Holdings EV to EBITDA ratio is 4.83, with an EV/FCF ratio of 11.34.
EV to Sales1.04
EV to EBITDA4.83
EV to Free Cash Flow11.34
EV to Operating Cash Flow5.53
Balance Sheet
Viva Biotech Holdings has HK$941.58M in cash and marketable securities with ¥1.28B in debt, giving a net cash position of HK$342.47M billion.
Cash & Marketable SecuritiesHK$941.58M
Total Debt¥1.28B
Net CashHK$342.47M
Net Cash Per ShareHK$0.16
Tangible Book Value Per ShareHK$0.61
Margins
Gross margin is 34.28%, with operating margin of 11.56%, and net profit margin of 8.42%.
Gross Margin34.28%
Operating Margin11.56%
Pretax Margin14.88%
Net Profit Margin8.42%
EBITDA Margin21.54%
EBIT Margin11.56%
Analyst Forecast
The average price target for Viva Biotech Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-9.75%
EPS Growth Forecast―